Cystic Fibrosis Foundation Therapeutics (CFFT) will provide up to $1.4 million to Pulmatrix to support Phase 1b trials of Pulmatrix’s lead candidate, PUR118, for the treatment of CF. The collaboration between the nonprofit affiliate of the Cystic Fibrosis Foundation and Pulmatrix also includes “introductions to world-class cystic fibrosis academic researchers and access to critical research insight and resources.”
PUR118 is a dry powder iCALM (inhaled cationic airway lining modulator) drug that Pulmatrix is also developing for asthma, influenza, and COPD. A Phase 1 study of PUR118 for CF and two Phase 1b studies for COPD are already underway.
Pulmatrix CEO Robert Clarke said, “We are honored that the CF Foundation recognizes the potential of PUR118 and is making an investment with Pulmatrix that will significantly enhance the drug’s development. This is a tremendous vote of confidence in our clinical program and gives us the ability to accelerate our activities as we seek to develop a novel treatment to meet the unmet needs of patients with CF. Longer term, we see PUR118 as a perfect complement to the existing CF therapies to provide even better patient outcomes.”
Read the Pulmatrix press release.
